Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France. With a strong international presence in 148 countries, Servier employs 21,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover in R&D and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes, and by its activities in high-quality generics.
Servier’s commitment to phlebology is long-lasting and contributes to a better understanding of the pathophysiology of chronic venous disorders, bringing a therapeutic solution for patients and doctors.